英语论文网

该报告是个人研究的一部分，它是用来补充我们的集团管理项目中中国全球制药行业在当前和未来扮演的角色。该报告通过提供来自像印度和中国一样的制药公司的不断竞争的理解，代表了我们的团队项目的个人组成部分。正如我们对于未来的构想一样，中国将要在2030年成为欧盟地区的主要药品供应商。通过对中国医药行业现状的分析，未来欧盟中一般市场的商机可以确定最佳的战略决策，通过衡量欧盟环境在未来几年与现存的中国公司运营合作情况。

全球市场可以分为两大类：管制的与非管制的/或者半管制的（Kumar和Akhilesh,2010,p.13）。被管制的市场由政府管理，比如像知识产权哦和和产品专利权，然而非管制或者半管制的市场是由现存的没水准或者更低水准管理。在被管制的市场中，通过价格和剧烈竞争的数量，以及对于出现不受管制的和半管制的市场类型来说设置的更低的进入门槛，提供了更大的稳定要素。

Current And Future State Of Chinas Pharmaceutical Industry

The report is part of the individual study made to complement our Group Management Project with an examination of China’s current and future role in the global pharmaceutical industry. The report represents the individual component of our group project by providing an understanding of the rising competition from pharmaceutical companies like India and China that is becoming the main source of pharmaceutical products in the European Union (‘EU’) region as outlined in our exploration of future scenarios for the region in the year 2030. Through the analysis of the current state of China’s pharmaceuticals industry, future businesses within the generics market in the EU can determine the best strategic decisions to make with consideration of the presence of the Chinese companies operating within the EU environment in the coming years.

The global pharmaceutical industry - overview

The global market can be classified into 2 categories: “regulated and unregulated / semi-regulated” (Kumar and Akhilesh, 2010, p.13). Examples of regulated would comprise of Government regulations e.g. intellectual property protection and product patents, while the unregulated/semi-regulated markets comprise of no/lower levels of regulations in existence. In regulated markets, there is a greater element of stability through price and volumes with heavy competition and lower entry barriers appearing for unregulated / semi regulated market category.

The pharmaceutical industry today is a highly competitive non-assembled industry with numerous players in every region around the world. With its origins traced back to the emerging chemical industry of the late 19th century near Basel, Switzerland, many of the early companies gradually moved on to pharmaceutical manufacturing to become global players that we know today. With the industry expanding rapidly since the 1960s - a result of booming healthcare spending, new medical discoveries and a lax regulatory oversight, the industry witnessed major developments in the 1970s with the introduction of regulations governing the production of ‘off-patented medicine’ otherwise known as ‘generics’.

Since the 1960s, the US government had made numerous efforts to ‘prove the safety and effectiveness of pharmaceuticals manufactured’ (GphA, 2010) which helped to launch the generic pharmaceutical industry. It was only until 1984 with the passage of the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as Hatch-Waxman that the generic industry truly blossomed (Chem-online, 2010). Hatch-Waxman created a framework for the more timely entry of generic drugs into the pharmaceutical market. Often referred to as the foundation of the modern generic pharmaceutical industry, the law encourages market competition between brand and generic companies, resulting in significant savings and more varieties for consumers. The presence of generic drugs has m本论文由英语论文网提供整理，提供论文代写，英语论文代写，代写论文，代写英语论文，代写留学生论文，代写英文论文，留学生论文代写相关核心关键词搜索。